Summary
This Form 8-K filing from Edwards Lifesciences Corporation, dated July 25, 2013, primarily serves to report the company's financial results for the second quarter of 2013. The report incorporates by reference a press release, Exhibit 99.1, which contains the detailed financial performance for the period. Investors should refer to this press release for comprehensive information regarding the company's operational and financial condition during the second quarter of 2013. While the 8-K itself is a brief regulatory filing, it signifies the public disclosure of key quarterly performance metrics. Investors would typically look to the accompanying press release for details on revenue, earnings per share (EPS), segment performance, and any forward-looking statements or guidance provided by the company. This filing ensures that material financial information is made available to the public in a timely manner.
Key Highlights
- 1Edwards Lifesciences filed an 8-K on July 25, 2013, to report its Q2 2013 financial results.
- 2The primary content of the filing is a press release (Exhibit 99.1) detailing the company's performance for the second quarter of 2013.
- 3The report confirms the disclosure of financial results as required by SEC regulations.
- 4The filing was signed by Thomas M. Abate, Corporate Vice President and Chief Financial Officer, indicating official company confirmation of the reported results.
- 5This filing is crucial for investors seeking to understand Edwards Lifesciences' financial health and operational performance during the specified quarter.